Neurizon Therapeutics Limited (ASX:NUZ)

Market Cap	59.08M
Revenue (ttm)	1.52M
Net Income (ttm)	-14.56M
Shares Out	492.31M
EPS (ttm)	-0.03
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	23,429
Average Volume	269,660
Open	0.1200
Previous Close	0.1250
Day's Range	0.1200 - 0.1200
52-Week Range	0.0960 - 0.2450
Beta	1.43
RSI	53.70
Earnings Date	Apr 17, 2025

About Neurizon Therapeutics

Neurizon Therapeutics Limited, a clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases in Switzerland, Australia, the United States, and internationally. The company develops drug discovery intellectual property for the treatment of various cancers and neurological diseases. Its lead candidate is Monepantel (MPL), a small molecule drug which is in Phase II clinical trials for the treatment of amyotrophic lateral sclerosis, as well as to treat other neurodegenerative diseases, such as Alzheimer’s and Parkinso...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 4
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: NUZ

Financial Performance

In 2024, Neurizon Therapeutics's revenue was 841,713, a decrease of -3.66% compared to the previous year's 873,653. Losses were -7.67 million, 23.5% more than in 2023.